Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephro
- PDF / 184,546 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 30 Downloads / 177 Views
ORIGINAL ARTICLE
Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology Etienne Bérard & Jean Luc André & Geneviève Guest & Frédéric Berthier & Mickael Afanetti & Pierre Cochat & Michel Broyer & On behalf of the French Society for Pediatric Nephrology Received: 22 November 2007 / Revised: 13 March 2008 / Accepted: 17 March 2008 / Published online: 27 June 2008 # IPNA 2008
Abstract Few publications have described the long-term effects of recombinant human growth hormone (rhGH) in uremic patients. This study reports the results of rhGH therapy at the end of treatment and at adult age in 178 French patients. At enrollment, 63 patients were under conservative treatment (CT), 40 under hemodialysis (HD), and 75 had a functioning renal transplant (RT). Under rhGH treatment, height velocities (HV) significantly increased in all patients, but the effect was significantly better in the CT Members of the French Society of Pediatric Nephrology: J.L. André, A. Bensman, E. Bérard, J.P. Bertheleme, F. Bouissou, B. Boudailliez, F. Brou, M. Broyer, A. Burguet, G. Champion, P. Cochat, M. Dehennault, G. Deschênes, P. Desprez, R. Dumas, M. Fischbach, M. Foulard, M.T. Freycon, M.F. Gagnadoux, S. Gié, G. Guest, C. Guyot, G. Landthaler, M.P. Lavocat, C. Loirat, M.A. Macher, D. Morin, C. Mousson, P. Niaudet, H. Nivet, J.B. Palcoux, G. Picon, B. Roussel, M. Tsimaratos E. Bérard (*) : M. Afanetti Service de Pédiatrie, CHU de Nice, Hôpital de l’Archet 2, 151 avenue de Saint Antoine Ginestière, BP 3079, 06202 Nice Cedex 3, France e-mail: [email protected] J. L. André Service de Néphrologie Pédiatrique, CHU de Nancy, Nancy, France G. Guest : M. Broyer Service de Néphrologie Pédiatrique, Hôpital des Enfants Malades, Paris, France F. Berthier Département d’Information Médicale, CHU de Nice, Nice Cedex 3, France P. Cochat Département de Pédiatrie, Hôpital Edouard Herriot, Lyon, France
group. The HV gain (HV under rhGH-HV before treatment) was similar in all three groups. Increases in HV allowed height standard deviation scores (SDS) catch up, and this effect persisted over a 5-year period. SDS height at the completion of treatment was significantly related to group (best in CT) and response to treatment during the first year. Data on adult height was available for 102 patients. Mean adult height was 162.2 cm in men and 152.9 cm in women, and 46% were > −2 SDS for height. Adult height SDS was correlated with height SDS and spontaneous HV before treatment and effect of treatment. Analysis of adult height in the 49 patients who entered the protocol with a height SDS between −2 and −3 (the current recommendation for rhGH use) revealed that 65% had an adult-height SDS >−2. These adult heights were significantly better if compared with historical cohorts of patients not treated by rhGH; rhGH significantly improves the adult-height prognosis of uremic patients suffering from growth retardation. Early rhGH administration during CT gives better height SDS at both the end of rhGH the
Data Loading...
